Evidence map›Paper›PMID 36192773›Full record

ArticleCancer & metabolism2022

ACSL3 regulates lipid droplet biogenesis and ferroptosis sensitivity in clear cell renal cell carcinoma.

Timothy D Klasson, Edward L LaGory, Hongjuan Zhao, Star K Huynh, Ioanna Papandreou, Eui Jung Moon, Amato J Giaccia

Open access · goldAbstract read
In one paragraph

Article in Cancer & metabolism, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers.

0numbers the graph read from it
0cells of the map it votes in
89citing papers in PubMed
10.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

89 citing papers in PubMed, 126 citations in OpenAlex.

  1. Review
  2. Ferroptosis as a target mechanism in heart and kidney disease.The Journal of clinical investigation · 2026
    Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review

29 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Timothy D Klasson *Department of Radiation Oncology, Stanford School of Medicine, Stanford University, Stanford, CA, 94305, USA.
Edward L LaGory *Department of Radiation Oncology, Stanford School of Medicine, Stanford University, Stanford, CA, 94305, USA.
Hongjuan ZhaoDepartment of Radiation Oncology, Stanford School of Medicine, Stanford University, Stanford, CA, 94305, USA.
Star K HuynhDepartment of Radiation Oncology, Stanford School of Medicine, Stanford University, Stanford, CA, 94305, USA.
Ioanna PapandreouDepartment of Radiation Oncology, The Ohio State Comprehensive Cancer Center, Columbus, OH, 43210, USA.
Eui Jung MoonDepartment of Radiation Oncology, Stanford School of Medicine, Stanford University, Stanford, CA, 94305, USA.
Amato J GiacciaDepartment of Radiation Oncology, Stanford School of Medicine, Stanford University, Stanford, CA, 94305, USA. amato.giaccia@oncology.ox.ac.uk.
Stanford University · USThe Ohio State University · USUniversity of Oxford · GB

Funding

The Impact of Mitochondrial Repression and Lipid Accumulation by HIF on Tumor GrowthR35CA197713 · NCI · STANFORD UNIVERSITY · PI GIACCIA, AMATO J. · 2015 to 2021
$5.3M
NCI NIH HHS R35 CA197713
6 · The paper itself

Abstract

backgroundClear cell renal cell carcinoma (ccRCC), the predominant subtype of kidney cancer, possesses characteristic alterations to multiple metabolic pathways, including the accumulation of cytosolic lipid droplets. However, the pathways that drive lipid droplet accumulation in ccRCC cells and their importance to cancer biology remain poorly understood.

methodsWe sought to identify the carbon sources necessary for lipid droplet accumulation using Oil red O staining and isotope-tracing lipidomics. The role of the acyl-CoA synthetase (ACSL) family members, an important group of lipid metabolic enzymes, was investigated using siRNA and drug mediated inhibition. CTB and XTT assays were performed to determine the effect of ACSL3 knockdown and lipid starvation on ccRCC cell viability and shRNA was used to study the effect of ACSL3 in an orthotopic mouse model. The relationship between ferroptosis susceptibility of ccRCC and ACSL3 controlled lipid metabolism was examined using CTB and FACS-based assays. The importance of 5-LOX in ferroptosis susceptibility in ccRCC was shown with XTT survival assays, and the expression level and predictive value of 5-LOX in TCGA ccRCC data was assessed.

resultsWe found that ccRCC cells obtain the necessary substrates for lipid droplet accumulation by metabolizing exogenous serum derived lipids and not through de novo lipogenesis. We show that this metabolism of exogenous fatty acids into lipid droplets requires the enzyme acyl-CoA synthetase 3 (ACSL3) and not other ACSL family proteins. Importantly, genetic or pharmacologic suppression of ACSL3 is cytotoxic to ccRCC cells in vitro and causes a reduction of tumor weight in an orthotopic mouse model. Conversely, ACSL3 inhibition decreases the susceptibility of ccRCC cells to ferroptosis, a non-apoptotic form of cell death involving lipid peroxidation. The sensitivity of ccRCC to ferroptosis is also highly dependent on the composition of exogenous fatty acids and on 5-lipoxygenase (5-LOX), a leukotriene producing enzyme which produces lipid peroxides that have been implicated in other cancers but not in ccRCC.

conclusionsACSL3 regulates the accumulation of lipid droplets in ccRCC and is essential for tumor growth. In addition, ACSL3 also modulates ferroptosis sensitivity in a manner dependent on the composition of exogenous fatty acids. Both functions of ACSL3 could be exploited for ccRCC therapy.

Indexed as

5-lipoxygenase (5-LOX)Acyl-CoA synthetase 3 (ACSL3)Clear cell renal cell carcinoma (ccRCC)FerroptosisLipid dropletsLipid metabolism

Identifiers

PMID36192773
PMCPMC9528056
OpenAlexW4300960565

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.